115 related articles for article (PubMed ID: 31611636)
1. Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer.
van Nuland M; Groenland SL; Bergman AM; Steeghs N; Rosing H; Venekamp N; Huitema ADR; Beijnen JH
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):244-251. PubMed ID: 31611636
[TBL] [Abstract][Full Text] [Related]
2. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients.
Carton E; Noe G; Huillard O; Golmard L; Giroux J; Cessot A; Saidu NE; Peyromaure M; Zerbib M; Narjoz C; Guibourdenche J; Thomas A; Vidal M; Goldwasser F; Blanchet B; Alexandre J
Eur J Cancer; 2017 Feb; 72():54-61. PubMed ID: 28027516
[TBL] [Abstract][Full Text] [Related]
3. A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients.
Blanchet B; Carton E; Alyamani M; Golmard L; Huillard O; Thomas-Scheomann A; Vidal M; Goldwasser F; Sharifi N; Alexandre J
Pharmacol Res; 2018 Oct; 136():56-61. PubMed ID: 30142421
[TBL] [Abstract][Full Text] [Related]
4. Cortisol as Biomarker for CYP17-Inhibition is Associated with Therapy Outcome of Abiraterone Acetate.
Bruin MAC; Mohmaed Ali MI; van Nuland M; Jacobs BAW; Lucas L; Dezentje VO; de Feijter JM; Rosing H; Bergman AM; Beijnen JH; Huitema ADR
Pharm Res; 2023 Dec; 40(12):3001-3010. PubMed ID: 37821768
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of the anticancer drug abiraterone and its metabolite Δ(4)-abiraterone in human plasma using high-resolution mass spectrometry.
Bhatnagar A; McKay MJ; Crumbaker M; Ahire K; Karuso P; Gurney H; Molloy MP
J Pharm Biomed Anal; 2018 May; 154():66-74. PubMed ID: 29533860
[TBL] [Abstract][Full Text] [Related]
6. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
[TBL] [Abstract][Full Text] [Related]
7. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M
BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821
[TBL] [Abstract][Full Text] [Related]
8. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
Leibowitz-Amit R; Templeton AJ; Omlin A; Pezaro C; Atenafu EG; Keizman D; Vera-Badillo F; Seah JA; Attard G; Knox JJ; Sridhar SS; Tannock IF; de Bono JS; Joshua AM
Ann Oncol; 2014 Mar; 25(3):657-662. PubMed ID: 24458472
[TBL] [Abstract][Full Text] [Related]
9. Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.
Verzoni E; De Giorgi U; Derosa L; Caffo O; Boccardo F; Facchini G; Porcu L; De Vincenzo F; Zaniboni A; Chiuri VE; Fratino L; Santini D; Adamo V; De Vivo R; Dinota A; Messina C; Ricotta R; Caserta C; Scavelli C; Susi M; Tartarone A; Surace G; Mosca A; Bruno M; Barni S; Grassi P; Procopio G
Oncotarget; 2016 Jun; 7(26):40085-40094. PubMed ID: 27223078
[TBL] [Abstract][Full Text] [Related]
10. Exosomal TUBB3 mRNA expression of metastatic castration-resistant prostate cancer patients: Association with patient outcome under abiraterone.
Zhu S; Ni Y; Sun G; Wang Z; Chen J; Zhang X; Zhao J; Zhu X; Dai J; Liu Z; Liang J; Zhang H; Zhang Y; Shen P; Zeng H
Cancer Med; 2021 Sep; 10(18):6282-6290. PubMed ID: 34318630
[TBL] [Abstract][Full Text] [Related]
11. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
Heck MM; Thaler MA; Schmid SC; Seitz AK; Tauber R; Kübler H; Maurer T; Thalgott M; Hatzichristodoulou G; Höppner M; Nawroth R; Luppa PB; Gschwend JE; Retz M
BJU Int; 2017 Jan; 119(1):30-37. PubMed ID: 27037533
[TBL] [Abstract][Full Text] [Related]
12. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients.
Ten Ham RMT; van Nuland M; Vreman RA; de Graaf LG; Rosing H; Bergman AM; Huitema ADR; Beijnen JH; Hövels AM
Value Health; 2021 Jan; 24(1):121-128. PubMed ID: 33431146
[TBL] [Abstract][Full Text] [Related]
14. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
[TBL] [Abstract][Full Text] [Related]
15. Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer.
Schiff JP; Cotogno P; Feibus A; Steinwald P; Ledet E; Lewis B; Sartor O
BMC Cancer; 2019 May; 19(1):524. PubMed ID: 31151428
[TBL] [Abstract][Full Text] [Related]
16. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
[TBL] [Abstract][Full Text] [Related]
17. Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67.
Zhao F; Zhao J; Wei X; Shi Y; Xu N; Zhu S; Chen J; Sun G; Dai J; Wang Z; Zhang X; Liang J; Hu X; Liu H; Zhao J; Liu Z; Nie L; Shen P; Chen N; Zeng H
Prostate; 2024 Jul; 84(10):932-944. PubMed ID: 38629249
[TBL] [Abstract][Full Text] [Related]
18. CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone.
Crucitta S; Del Re M; Paolieri F; Bloise F; Sbrana A; Sammarco E; Mercinelli C; Cucchiara F; Fontanelli L; Galli L; Danesi R
Cancer Chemother Pharmacol; 2020 Oct; 86(4):527-533. PubMed ID: 32945940
[TBL] [Abstract][Full Text] [Related]
19. Clinical activity of abiraterone plus prednisone in docetaxel-naοve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer.
Lin GW; Li GX; Dai B; Ye DW; Kong YY; Wang Y; Shen YJ
Asian J Androl; 2019; 21(2):131-136. PubMed ID: 30560837
[TBL] [Abstract][Full Text] [Related]
20. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
